BioAge Labs, Inc. BIOA
5.22 USD -0.33 (-5.95%)
Regular-session close
5.30 +0.08 +1.53%
Pre-market · Nov 17, 7:17 AM ET
5.08 Day range 5.64
4.81 52-week range 25.96
- YTD
- -60.54%
- 1 year
- -33.08%
News
seekingalpha.com BioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 Transcript BioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 Transcript
defenseworld.net Sol-Gel Technologies (NASDAQ:SLGL) vs. BioAge Labs (NASDAQ:BIOA) Critical Contrast Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and BioAge Labs (NASDAQ: BIOA - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the…
globenewswire.com BioAge Labs to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates…benzinga.com Piper Sandler Maintains Overweight on Bioage Labs, Lowers Price Target to $40 Piper Sandler analyst Yasmeen Rahimi maintains Bioage Labs (NASDAQ:BIOA) with a Overweight and lowers the price target from $73 to $40.
benzinga.com Bioage Labs Q3 EPS $(0.73) Misses $(0.59) Estimate, Sales $298.000K Miss $1.644M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.59) by 23.73 percent. This is a 30.36 percent decrease over losses of…
benzinga.com BioArctic AB Announces Novartis Terminates Their 2025 Option, Collaboration And License Deal; BioArctic To Retain Full $30M Upfront Payment BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered…
